←
Jay Caplan1,382 posts
Jay Caplan avatar

Jay Caplan

@jdcaplan

Biotech and Medtech founder | X opinions/posts are my own.

◷ Joined May 2013▧ 25 Photos and videos
Chris Thompson, MD avatar
⟳ Jay Caplan retweeted
Chris Thompson, MD@MetabolicEndo·Sep 22

The gut is much more than a digestive organ. It is a metabolic sensing and signaling system that helps shape how we respond to food, regulate appetite, and control metabolism. Really enjoyed going deep on this with Andrew Huberman, from gut biology and the microbiome to obesity, GLP-1 therapies, and endoscopic treatments.

The new Huberman Lab episode is out: Best Tools for Gut Health and Weight Loss | Dr. Chris Thompson 0:00 Dr. Chris Thompson 2:16 Digestive Tract, Gut Hormones & Nutrient Absorption 8:06 Colon Microbiome & Colon Cancer Screening 11:13 Sponsors: LMNT & Lingo 13:40 Swallowing Problems & Zenker's Diverticula 16:08 Bowel Movements & Constipation 18:28 Fiber, Resistant Starch & the Gut Barrier 21:50 Intermittent Fasting & the Gut Microbiome 23:38 Fermented Foods, Microbial Diversity & Butyrate 27:12 H. pylori, Stress & Stomach Ulcers 30:20 GLP-1 Medications: Benefits & Limitations 33:42 Lower GLP-1 Doses, Weight Regain & Muscle Loss 37:35 GLP-1 Side Effects, Food Noise & Apathy 39:49 Bariatric Surgery & Medical Innovation 46:07 Sponsor: AG1 47:44 Hunger & Satiety: Ghrelin, CCK, GIP & GLP-1 50:01 Retatrutide & Combining Hormonal Targets 52:55 Ultra-Processed Foods, Overeating & Leptin 55:32 Incretin Discovery, Exendin-4 & the Gila Monster 59:35 Endoscopic Ultrasound & Pancreatic Biopsy 1:07:40 Early Metabolic Markers, CGMs & Fasting Insulin 1:13:06 Insulin Resistance & Metabolic Flexibility 1:15:53 Sponsor: Function 1:17:35 Patient Data, Screening & Treatment Adoption 1:26:31 AI, Robotics & Improving Procedures 1:29:27 Choosing a Surgeon & Measuring Procedure Quality 1:35:29 Image Guidance & Hyperspectral Imaging 1:37:19 Sponsor: Our Place 1:38:56 Diagnostics & Targeted Metabolic Treatments 1:42:45 Gastric Bypass, Foregut Exclusion & Diabetes 1:47:59 Duodenal Liners & Mucosal Resurfacing Research 1:52:58 Gut Permeability, Inflammation & Fatty Liver 1:59:39 Artificial Sweeteners, Fructose, Fats & Omega-3s 2:05:00 Resistance Training, Zone 2 Cardio & Intervals 2:06:31 Weight Set Point & Metabolic Adaptation 2:08:13 Endoscopic Sleeve Gastroplasty & Fundus Ablation 2:10:30 Magnetic Intestinal Connections & Combined Treatments 2:16:52 GLP-1 Gene Therapy Research 2:22:13 Innovation, Problem Solving & Teamwork 2:25:58 Zero-Cost Support, Sponsors & Neural Network Newsletter Includes paid partnerships.

2:27:53
Partha S Kar 🇮🇳🇬🇧🏏🎥 avatar
⟳ Jay Caplan retweeted
Partha S Kar 🇮🇳🇬🇧🏏🎥@parthaskar·Aug 2

The work never stops- it shouldn't stop either. Something to help the #T1diabetes community - across #NHS A little thing I have been working on based on feedback from many over the years- around travel, airport security and living with #T1D If you already have something robust in place for all travels? No need to change If you don't? This hopefully helps Please use, cascade and discuss with clinicians as needed. Letter sent out across NHS (H/T @semarroy72 for the idea and the push) Regards Partha @BT1DUK @DiabetesUK @DiabeticDadUK @diabetes_chat @DRWFDiabetes @mbrp1 @sugarydoc

Post attachmentPost attachment
Germania Rodriguez Poleo avatar
⟳ Jay Caplan retweeted
Germania Rodriguez Poleo@iamGermania·Jun 30

I'm passionate about showing the privileged citizens of western democracies the horrors of socialism because I know what it's like to fall for the propaganda. thank you @reason for letting me tell this personal story about my political journey to and from the left. reason.com/2026/06/30/my-fam…

Jeffrey Flier avatar
⟳ Jay Caplan retweeted
Jeffrey Flier@jflier·Jun 6

Diabetes researchers ejected from conference after criticizing White House. The editor of ADA journal Steve Kahn was nondisruptivedly handing out his recent editorial in ADA journal that criticized Trump NIH policies. Big mistake by @AmDiabetesAssn washingtonpost.com/health/20…

Steven Kahn avatar
⟳ Jay Caplan retweeted
Steven Kahn@StevenKahn11·Jun 6

I grew up in apartheid S Africa, where muzzling of speech and encroachment on academic freedom were the norm. I came to the US to pursue a career in science. I never thought that at this stage of my career, I would ever experience my youth again. #StandUpForScience #ADA #ADA2026

Shailendra Singh avatar
⟳ Jay Caplan retweeted
Shailendra Singh@shailsingh·May 2

Looking forward @DDWMeeting. Exciting parts of #DDW is seeing innovative technologies that have the potential to truly change patient outcomes Check out @FractylHealth Duodenal Mucosal Resurfacing (DMR) — science, actual procedure, and what lies ahead in metabolic endoscopy

Post attachment
Daniel J Drucker avatar
⟳ Jay Caplan retweeted
Daniel J Drucker@DanielJDrucker·Mar 21

People with #T1D deserve P3 clinical trials to study the cardioprotective and kidney-sparing actions of GLP-1 medicines nature.com/articles/s41591-0…

Daniel J Drucker avatar
⟳ Jay Caplan retweeted
Daniel J Drucker@DanielJDrucker·29 Dec 2025

Joel Habener @MassGeneralNews @Harvard at one of the lab social gatherings in the mid 1980s with one of the labs talented research fellows, currently the President of @Penn Larry Jameson

Post attachment

Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ⁦@MassGeneralNews⁩ ⁦@TheEndoSociety⁩ ⁦@Harvard⁩ wsj.com/health/pharma/joel-h…

Daniel J Drucker avatar
⟳ Jay Caplan retweeted
Daniel J Drucker@DanielJDrucker·29 Dec 2025

Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ⁦@MassGeneralNews⁩ ⁦@TheEndoSociety⁩ ⁦@Harvard⁩ wsj.com/health/pharma/joel-h…

Scott Gottlieb, MD 🇺🇸 avatar
⟳ Jay Caplan retweeted
Scott Gottlieb, MD 🇺🇸@ScottGottliebMD·4 Dec 2025

12 former commissioners of the FDA came together to write a Perspectives piece for the New England Journal of Medicine; raising our concerns about recent changes to vaccine approval policy at the FDA and its implications for patients and public health.

Post attachmentPost attachmentPost attachment
Chris Thompson, MD avatar
⟳ Jay Caplan retweeted
Chris Thompson, MD@MetabolicEndo·3 Sep 2025

Honored to join the Board of Fractyl Health at such a pivotal moment. Revita® is advancing through late-stage development, and Rejuva® is preparing for first-in-human studies. Fractyl is redefining how we treat obesity and type 2 diabetes by addressing root causes, not just symptoms. Excited to help shape this next chapter.

Harith Rajagopalan avatar
⟳ Jay Caplan retweeted
Harith Rajagopalan@Harithr·3 Sep 2025

Welcoming @MetabolicEndo and Ian Sheffield to our Board marks an important moment for Fractyl. Their expertise in pioneering new approaches to obesity care and in building healthcare businesses with lasting impact will help guide us through this next stage of growth. I’m also grateful to Amy Schulman for her service and leadership on our Board, and for helping position Fractyl to seize the opportunities ahead. Looking forward to the journey as we continue advancing Revita® and Rejuva® toward our goal of transforming metabolic care. $GUTS #FractylForward Revita® is for Investigational Use Only in the U.S. under Federal law. Rejuva® is in preclinical development and has not yet been assessed by regulatory agencies.